As the current situation with COVID-19 develops and spreads fast, thousands of researchers and volunteers worldwide are working to search for a vaccine.
Optimism for finding the possible cure for Coronavirus has been growing since many clinical trials are in progress in order to evaluate potential treatments and their efficacy. One of the leading candidates for COVID-19 is being developed in the UK by Oxford University researchers.
The Oxford COVID 19 vaccine technology team is led by Sarah Gilbert, Prof Andrew Pollard, Prof. Teresa Lambe, Prof. Catherine Green, Prof Adrian Hill, and Dr. Sandy Doughlas. The professional team of scientists is working together in vaccine research.
About the Oxford COVID 19 vaccine results, more than 1,000 immunizations were given in the U.K during the phase I trial in healthy adult volunteers. In phase II oxford COVID 19 vaccine trial, the study expands as the age range of people participating includes a small number of older adults and children. This trial is a step to find out if the immune response to the vaccine in people of different ages.
As per the Oxford COVID, 19 vaccine update, the two Mumbai based institutes – King Edward Memorial Hospital and BYL Nair Hospital have started the preliminaries of conducting the Oxford University-AstraZeneca Covid-19 vaccine trial.
The Serum institute in India has partnered with Oxford-AstraZeneca and is already in the process of manufacturing 2-3 million doses by August end of 2020. There will be a total of 17 institutions in India to participate in the trial to be conducted by the Serum Institute of India, Pune.
With the approval from the government of India, it is going to conduct final-phase human trials from August 2020. The purpose of Phase II/III is to check if a vaccine made from the weakened virus that causes the common cold in Chimps can protect from COVID.
The Covid-19 vaccine by Oxford is called AZD122 and will be manufactured and distributed in India as the Covishield vaccine which is going to cost less than 1000 INR per dose. The vaccine candidate was one of the first candidates to have begun the clinical trial stage that is currently undergoing phase 3 of the trials somewhere in Brazil.
By the end of 2020, it has also been expected to have at least 50 million Covishield doses ready, more than half of which will be supplied to the government of India with the rest being provided to the other countries, more specifically to the less developed nations.
John Bell (Professor of medicine at the University of Oxford) said “The UK is in search of a place in the world to prove leadership in the vaccine space. John is working with the UK government on its vaccine program.
Who can participate in the Oxford COVID 19 vaccine trial? The sample size is expected to be 16000 people, out of which 400 for immune response study and 1200 to gauge safety. People from the age group 18 to 99 years participate. There is no restriction for gender as both males and females are permitted to take part in the trial.
Oxford COVID 19 vaccine results induce strong antibody and T-cell immune responses for up to 56 days after administering it. As per the report, T-cells are required for maintaining protection against the virus for years.
Good immune response has been observed in almost everybody in people aged 18 to 55 said by Dr. Adrian Hill, who is the director of the Jenner Institute at Oxford University and he added that the experimental Covid-19 produced dual response along with producing neutralizing antibodies required to block infection.
Whom to contact?
For the King Edward Memorial Hospital, call at 022-24133767, 24174420.
For the BYL Nair Hospital, contact at (022-23027644, 45)